Corporate History Timeline

Gilead acquires Branford, Connecticut-based CGI Pharmaceuticals.

The U.S. Food and Drug Administration approves Cayston^® for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.

The U.S. Food and Drug Administration approves Viread^® for chronic hepatitis B in adults.

European Medicines Agency approves Viread^® for the treatment of chronic hepatitis B.

European Medicines Agency approves Atripla^® for the treatment of HIV.

Gilead and LG Life Sciences, Ltd. enter into an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases.

Atripla approved by Health Canada.

Gilead acquires Cork, Ireland manufacturing facility from Nycomed.

The U.S. FDA approves Letairis^® for the treatment of pulmonary arterial hypertension.

Gilead’s Board of Directors approves a two-for-one stock split.

Gilead acquires Edmonton, Alberta-based Raylo Chemicals.

Gilead acquires Westminster, Colorado-based Myogen.

Gilead acquires Seattle, Washington-based Corus Pharma.

Gilead announces licensing agreements with India-based companies for manufacturing and distribution of generic versions of Viread ^® in the developing world.

The U.S. Food and Drug Administration approves Atripla^®, the first once-daily single tablet regimen for adults with HIV-1 infection.

The U.S. Food and Drug Administration approves Ranexa^® for the treatment of chronic angina.

Gilead expands its Access Program to include additional countries in the Caribbean and Latin America, meaning that 97 countries, representing an estimated 70 percent of the global HIV/AIDS epidemic, are now included in the company’s access effort.

Gilead establishes non-profit Foundation, with a mission of improving access to healthcare for people around the world.

European Medicines Agency approves Truvada^® for the treatment of HIV.

The U.S. FDA approves Macugen^® for age-related macular degeneration.

The U.S. FDA approves Truvada^®, a one-tablet, once-a-day fixed-dose co-formulation of Emtriva and Viread for HIV combination therapy.

Truvada is added to Gilead's Access Program and U.S. Advancing Access Program.

Gilead's Board of Directors approves a two-for-one stock split.

Gilead Sciences is added to the S&P 500^®.

European Medicines Agency approves Emtriva^® for the treatment of HIV

The U.S. FDA approves Emtriva^® for the treatment of HIV.

Gilead launches its Access Program to provide the anti-HIV therapy Viread^® in 68 developing countries at significantly reduced prices.

European Medicines Agency approves Hepsera^® for the treatment of chronic hepatitis B.

Gilead acquires Durham, North Carolina-based Triangle Pharmaceuticals.

The U.S. FDA approves Hepsera^® for the treatment of chronic hepatitis B.

Gilead's Board of Directors approves a two-for-one stock split.

European Medicines Agency approves Viread for the treatment of HIV infection.

Gilead reports first year of positive cash flow from operations.

The U.S. FDA approves Viread^® for the treatment of HIV infection.

Gilead's Board of Directors approves a two-for-one stock split.

The U.S. FDA approves AmBisome^® for the treatment of cryptococcal meningitis in HIV-infected patients.

The U.S. FDA approves Tamiflu^® for the treatment of influenza A and B in adults.

Gilead acquires Boulder, Colorado-based NeXstar Pharmaceuticals and establishes international operations.

The U.S. FDA approves Vistide^® for treatment of cytomegalovirus retinitis in patients with AIDS.

Gilead completes its initial public offering of 5.75 million shares of Common Stock, for total proceeds of $86.25 million.

Gilead in-licenses nucleotides from The Institute of Organic Chemistry and Biochemistry at the Academy of Sciences of the Czech Republic and Rega Stichting. 

AmBisome^® liposome for injection receives first approval in Europe for the treatment of severe fungal infections.

Gilead Sciences is founded.